HPV Vaccines: Costs and Financing

摘要: The purpose of this paper is to review the major cost and financing challenges for introduction human papillomavirus (HPV) vaccines in developing countries present possible next steps addressing those challenges. HPV vaccine prices will be much more expensive than traditional Expanded Program on Immunization (EPI) likely “newer” such as Hib Hep B. There also significant non-vaccine delivery costs since reaching target group, preadolescents, with three doses require innovative approaches. poorest countries, least ability pay, have largest cohorts preadolescent girls a share their total population. Decision makers need weigh priority against other health priorities, well entering market. In doing so, they consider, among factors, costs, cost-effectiveness, programmatic feasibility, financial sustainability. Global Alliance Vaccines (GAVI) could source external assistance if approved eligibility by GAVI Board. Preparation clear compelling investment case critical. A strong argument made at country level. Middle-income that are not GAVI-eligible look domestic resources sources introduce vaccines. Strong signals commitment give manufacturers assurance can scale up production meet requirements. This background was prepared International AIDS Vaccine Initiative (IAVI) December 12-13, 2006 meeting: “Stop Cervical Cancer: Accelerating Access vaccines.” Meeting organized Health Strategies H. Saxenian & R. Hecht/ Stop Cancer